- Greater average weight loss: Zepbound (tirzepatide), 20–22% vs. 15–17% for Wegovy
- Longer track record: Wegovy, FDA-approved June 2021 vs. Zepbound November 2023
- Cardiovascular outcomes data: Wegovy — the SELECT trial showed a 20% MACE reduction
- Brand cost (no insurance): Both approximately $1,000–$1,500/month
- Compounded cost at Luma Health: Semaglutide $90/mo · Tirzepatide $165/mo
The FDA-Approved Obesity Medications: Background
Both Wegovy and Zepbound represent a class of obesity pharmacotherapy that has fundamentally changed what's medically possible for weight management. For decades, the only FDA-approved weight loss drugs offered modest 5–8% weight reduction. These two medications changed that ceiling dramatically.
Wegovy (semaglutide 2.4mg injection) was approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It's manufactured by Novo Nordisk, the same company that makes Ozempic (semaglutide for type 2 diabetes). Wegovy is the weight-loss branded version of the semaglutide molecule.
Zepbound (tirzepatide injection) was approved by the FDA in November 2023 for the same weight management indication. It's manufactured by Eli Lilly, the same company that makes Mounjaro (tirzepatide for type 2 diabetes). Zepbound is the weight-loss branded version of the tirzepatide molecule.
Both medications are prescription-only, require weekly subcutaneous self-injections, and are intended for long-term use as part of a comprehensive weight management program. Neither is a cure — discontinuation typically results in some degree of weight regain.
Drug Profiles: Wegovy and Zepbound
How They Work: Mechanism Comparison
Understanding why these drugs produce different weight loss outcomes requires understanding their mechanisms. Both work primarily by slowing gastric emptying, suppressing appetite via the hypothalamus, and improving insulin sensitivity — but tirzepatide adds a second mechanism that semaglutide lacks.
Semaglutide (Wegovy) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating. It signals the brain to reduce hunger, slows the movement of food from the stomach to the small intestine, and stimulates insulin release in a glucose-dependent manner. Semaglutide mimics this hormone with high structural homology to human GLP-1, but with modifications that extend its half-life to approximately one week, enabling once-weekly dosing.
Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor (the same mechanism as semaglutide) and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in energy homeostasis and fat metabolism. The dual activation is believed to work synergistically — the GIP component may enhance the brain's response to GLP-1 signaling, amplify fat metabolism in adipose tissue, and improve the overall appetite-suppressing effect. This dual mechanism is widely credited with tirzepatide's superior weight loss outcomes in clinical trials.
Clinical Results: STEP vs SURMOUNT Trials
Wegovy: The STEP Trial Program
Wegovy's FDA approval was supported by the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. The pivotal STEP-1 trial enrolled 1,961 adults with obesity or overweight plus comorbidities (without diabetes) and randomized them to semaglutide 2.4mg or placebo for 68 weeks. Average weight loss was approximately 14.9% of body weight with semaglutide vs. 2.4% with placebo. Approximately 69.1% of participants achieved at least 10% weight loss, and 50.5% achieved at least 15% weight loss.
The SELECT trial extended Wegovy's clinical profile by demonstrating a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and obesity. This cardiovascular outcomes data is currently unique to semaglutide among weight loss medications — Zepbound does not yet have an equivalent published long-term cardiovascular outcomes trial.
Zepbound: The SURMOUNT Trial Program
Zepbound's approval was supported by the SURMOUNT trial program. The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight plus comorbidities (without diabetes), randomized to tirzepatide 5, 10, or 15mg weekly or placebo for 72 weeks. At the 15mg dose, average weight loss was approximately 20.9% of body weight. At 10mg, weight loss averaged approximately 19.5%; at 5mg, approximately 15.0%. Nearly 37% of patients on the highest dose achieved 25% or more body weight loss — a threshold previously only achievable with bariatric surgery.
The direct head-to-head trial, SURMOUNT-5, compared tirzepatide (10mg and 15mg) to semaglutide 2.4mg in adults with obesity. Results showed tirzepatide produced average weight loss of approximately 20.2% vs. 13.7% with semaglutide — a statistically significant difference. Tirzepatide was superior to semaglutide on all pre-specified weight loss endpoints in this trial.
Clinical Results Comparison
| Metric | Wegovy (STEP-1) | Zepbound (SURMOUNT-1) |
|---|---|---|
| Average weight loss | 14.9% | 20.9% (15mg dose) |
| ≥10% weight loss | 69.1% | 91.8% |
| ≥15% weight loss | 50.5% | 81.4% |
| ≥20% weight loss | 32.0% | 56.8% |
| ≥25% weight loss | N/A | 36.9% |
| Trial duration | 68 weeks | 72 weeks |
| CV outcomes data | Yes (SELECT trial) | Pending |
| Head-to-head winner (SURMOUNT-5) | — | Zepbound: 20.2% vs. 13.7% |
Side Effect Profiles
Both Wegovy and Zepbound share a similar core side effect profile because both work through the GLP-1 pathway. The most common adverse effects are gastrointestinal and occur primarily during dose escalation.
| Side Effect | Wegovy | Zepbound |
|---|---|---|
| Nausea | 44% | 35–45% |
| Diarrhea | 30% | 23–30% |
| Vomiting | 24% | 11–25% |
| Constipation | 24% | 17–22% |
| Trial dropout (adverse events) | ~7–8% | ~7–9% |
Most patients tolerate both medications well, particularly at lower doses. Slow titration, eating smaller meals, staying hydrated, and timing the injection in the evening can all help manage early side effects.
⚠ Important Safety Note
Both Wegovy and Zepbound carry a boxed warning regarding thyroid C-cell tumors based on rodent studies. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Tell your provider about all other medications you take. Both also carry warnings related to pancreatitis and gallbladder disease.
Cost: Brand-Name vs. Compounded Pathways
Both Wegovy and Zepbound list at approximately $1,000–$1,500/month without insurance — among the most expensive prescription medications on the market for a chronic condition. Insurance coverage for weight loss indications varies enormously by plan, with many employer plans excluding GLP-1 weight loss coverage entirely or requiring extensive prior authorization. Manufacturer savings cards can reduce out-of-pocket costs for eligible commercially insured patients, but eligibility criteria exclude many cash-pay patients.
For patients without meaningful insurance coverage, compounded versions of the same active ingredients — dispensed under the FDA 503A compounding pathway by licensed pharmacies — offer a dramatically lower-cost alternative. Luma Health offers compounded semaglutide at $90/month and compounded tirzepatide at $165/month, both prepared by VialsRX, a licensed 503A sterile compounding pharmacy, under prescription from Wasef Health, PC.
Who Should Choose Wegovy
- You have established cardiovascular disease and specifically want the SELECT trial's documented MACE risk reduction
- Your insurance covers Wegovy with a manageable copay
- You qualify for Novo Nordisk's savings card program
- You prefer the medication with the longer FDA-approval track record
Who Should Choose Zepbound
- You want the maximum available weight loss — the dual GIP/GLP-1 mechanism produces meaningfully greater results in head-to-head trial data
- You've tried semaglutide and plateaued before reaching your goal
- Your insurance covers Zepbound, or you qualify for Eli Lilly's savings card or LillyDirect program
- You have significant obesity-related comorbidities where maximizing weight loss meaningfully changes your health outlook
💡 The compounded alternative: If brand-name cost or insurance coverage is the deciding factor rather than a specific clinical preference, compounded versions of the same active ingredients through Luma Health ($90–$165/month) deliver the identical molecule at a fraction of brand-name pricing — worth discussing with a licensed clinician regardless of which active ingredient you ultimately choose.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM. 2021;384:989–1002.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). NEJM. 2022;387:205–216.
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). NEJM. 2023;389:2221–2232.
- Aronne LJ, et al. SURMOUNT-5 head-to-head tirzepatide vs. semaglutide trial in adults with obesity. JAMA. 2024.
Frequently Asked Questions
Based on clinical trial data, yes — including the direct head-to-head SURMOUNT-5 trial, which showed tirzepatide produced approximately 20.2% average weight loss vs. 13.7% with semaglutide. However, individual responses vary considerably, and some patients achieve excellent results on semaglutide that exceed the tirzepatide average.
Yes — Wegovy has published cardiovascular outcomes data from the SELECT trial showing a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and obesity. Zepbound does not yet have an equivalent published long-term cardiovascular outcomes trial, though research in this area continues.
The side effect profiles are broadly similar since both work through the GLP-1 pathway — nausea, diarrhea, vomiting, and constipation are common to both during dose escalation. Reported rates are comparable, with Zepbound showing slightly lower rates for some GI symptoms in trial data, though individual experience varies.
Yes, switching between these medications is common and can be done under medical supervision. Your provider will typically start you at the lowest dose of the new medication regardless of your previous dose, since the two drugs aren't directly equivalent on a milligram basis.
For cash-pay patients without meaningful insurance coverage or savings card eligibility, compounded versions of the same active ingredients (semaglutide or tirzepatide) through licensed 503A compounding pharmacies offer the lowest-cost legitimate pathway. Luma Health offers compounded semaglutide at $90/month and compounded tirzepatide at $165/month.
Eli Lilly priced Zepbound somewhat below Wegovy's list price at launch, partly reflecting competitive positioning in a market where Novo Nordisk had already established Wegovy. Both remain expensive relative to most prescription medications, and actual patient cost depends heavily on insurance coverage and savings card eligibility rather than list price alone.